MRCT and Biolex Complete Humanization of New Antibody
Posted on: Tuesday, 15 July 2008, 09:01 CDT
Medical Research Council Technology and Biolex Therapeutics have announced that MRCT has successfully completed the humanization of a novel antibody targeting CD20, indicated in non-Hodgkin's lymphoma and rheumatoid arthritis.
Biolex is applying its proprietary glycosylation optimization technology to the antibody, BLX-301, to enhance efficacy and potency of the product candidate and potentially reduce certain side effects.
Biolex will retain all development and commercialization rights to the humanized antibody, and Medical Research Council Technology (MRCT) will receive regulatory milestone payments and royalties upon its successful development.
Jan Turek, president & CEO of Biolex, said: "Applying the glycosylation optimization capabilities of our LEX System to a humanized antibody provides the potential for a next-generation product that offers a therapeutic advantage while also addressing the relatively low potency and problematic side-effect burden of the current standard of care."
Source: Datamonitor
Related Articles
- MRC Technology and Biolex Therapeutics Successfully Complete Collaboration to Humanize a Novel Antibody Targeting CD20
- Biolex Therapeutics Enters Into Agreement With Merck KGaA for Antibody Optimization
- Biolex Researchers Present Results of Anti-CD20 Antibody With Optimized Glycosylation at ASH Conference
- Biolex Therapeutics Announces Agreement With Genmab for New Class of Antibodies
- Biolex Therapeutics' LEX System(SM) Featured in Breakout Session at the 2007 BIO International Convention
- Biolex Therapeutics Featured at Next Generation Antibody Panel at BIO CEO & Investor Conference
- Biolex Announces Publication in Nature Biotechnology Demonstrating Potential To Produce Monoclonal Antibodies With Increased Potency and Efficacy
- Medarex Expands Collaboration With Biolex
- Biolex Therapeutics Announces Expansion of Medarex Collaboration
 |
 |
User Comments (0)
RSS Feeds